280E treatment,
defensible structures.

Financial and tax advisory for licensed California cannabis operators breaks cleanly into four operational areas. These are our named responsibilities — not “tax strategy” platitudes. Where we own, we draft the memorandum, model the structure, reconcile the filings, and organize the exam file. Where you own, we coordinate in support but the tax return, the capital decision, and any privileged legal position are yours.

Escalation path

When work crosses into privileged tax analysis — IRS exam representation, contested CDTFA assessments, Tax Court matters, or securities-law aspects of a capital raise — we coordinate with your tax counsel or introduce one from our retained network. We also coordinate with your CPA on return-level positions; we do not prepare or sign returns. The engagement letter names this boundary from day one.

How we draw the boundary with you

You own: the tax returns themselves (your CPA signs), pricing and capital decisions, investor and lender relationships. We own: the four areas above. Where a return-level position is your CPA’s call but has structural implications, we document our analysis so the CPA decision is informed. Where a raise or M&A structure has tax implications, we model those before counsel drafts documents.

What’s explicitly out of scope

Tax return preparation, tax filings, IRS representation (Circular 230 practice), securities-law compliance, and investment advice are not within the scope of this engagement. We are not CPAs, attorneys, or registered investment advisors. Those are specialist roles with their own licensing; we coordinate with them but do not perform their work.

The engagement runs through five named milestones over four weeks plus ongoing quarterly coordination. Financial and tax advisory for California cannabis sits at the uncomfortable intersection of federal 280E, California-specific R&T conformity, and the post-AB 195 excise regime. The milestones below produce a tax position that compounds savings across the 280E-conforming period while keeping the record exam-ready in case IRS chooses to audit.

Milestones, in detail

• Week 1 — Current-state tax review. Current 280E treatment analyzed line-by-line against IRC 280E, IRC 471, IRC 263A, and the governing case law (Champ, Olive, Patients Mutual, Alternative Healthcare Advocates, Harborside). CDTFA cannabis-tax filings reviewed against METRC transfers and GAAP revenue. Local cannabis-business-tax filings reconciled. Baseline memo identifies both exposure and opportunity.
• Week 2 — 280E exposure analysis. Chart of accounts annotated with IRC 471 and 263A treatment, direct and indirect cost allocation worksheets, absorption-method documentation. Savings opportunities identified with quantified before-and-after tax impact. Typical engagement surfaces $40K–$300K annual federal-tax savings for operators grossing $8M–$60M.
• Week 3 — Cost-segregation study. Engineering-based cost-segregation analysis for cannabis facility capital assets. Personal property, land improvements, and building components separated for accelerated depreciation under MACRS. For extraction-heavy manufacturers and indoor cultivators, cost-seg typically pays for itself inside the first year through year-one depreciation acceleration.
• Week 4 — Structure recommendations. C-corp, pass-through, and licensed-plus-management-company scenarios modeled against specific 280E and California R&T outcomes. Trade-off table with owner-level cash flow. Recommendation memo with supporting rationale. Where structural change is warranted, transition plan coordinated with your counsel and CPA.
• Ongoing — Quarterly CPA coordination. Quarterly CDTFA reconciliation, local-tax reconciliation, 280E file maintenance, and audit-readiness updates. Coordination call with your CPA every quarter to align on positions taken and to refresh the IRS-exam file. Capital-raise and M&A tax positioning produced on demand.

Duration and rhythm

Standard initial engagement runs four weeks to deliver the baseline memo, cost-seg study, and structure recommendation. Ongoing quarterly coordination runs $1,500–$3,500 per quarter. Urgent engagements (pre-audit, pre-diligence, pre-raise) can compress the initial timeline to two weeks at an urgency premium. We coordinate with your existing CPA or, if you don’t have a cannabis-specialized one, introduce one from our network.

Who you work with each phase

A named principal owns the engagement and signs every memorandum. A tax analyst handles COGS allocation worksheet construction, CDTFA reconciliation, and cost-seg coordination. Your CFO or controller is the primary contact; your CPA of record is looped in on every memo and reconciliation. Tax counsel is looped in on structural recommendations that involve related-party pricing or management-company carveout. We are not CPAs and do not prepare returns — that stays with your CPA of record.

When we finish this engagement, you’ll have a specific set of tax-position memoranda, reconciled filing records, and structural documentation in your possession. These are not “tax strategy slide decks.” They are working documents your CPA can rely on, your auditor can read without confusion, and your investors can review during diligence without raising flags.

The ten outputs, in detail

• 280E treatment review memorandum. Current 280E treatment analyzed line-by-line against IRC 280E, IRC 471, IRC 263A, and the Champ/Olive/Patients Mutual/Alternative Healthcare Advocates case law. Savings opportunities identified with quantified before-and-after tax impact. Typical length: 20–40 pages. Delivered to CPA of record.
• COGS / inventoriable-cost allocation file. Chart of accounts annotated with IRC 471 and 263A treatment, direct and indirect cost allocation worksheets, absorption method documentation, and the narrative support that holds up under IRS exam. Updated quarterly.
• Entity structure review. C-corp, pass-through, and licensed-plus-management-company scenarios modeled against specific 280E and California R&T outcomes. Trade-off table with owner-level cash flow. Recommendation memo with supporting rationale.
• Cost-segregation study. Engineering-based cost-segregation analysis for cannabis facility capital assets — personal property, land improvements, and building components separated for accelerated depreciation under MACRS. Typical payback inside year one.
• California cannabis excise & CDTFA reconciliation. Quarterly CDTFA cannabis tax filings reviewed for accuracy, reconciled against METRC transfers and GAAP revenue. Post-AB 195 retailer-collection compliance verified. Local cannabis business tax reconciled on the same base.
• Audit-readiness packet. 280E exam file assembled and maintained: treatment memo, COGS file, related-party agreements, entity diagram, tax-position narratives, exhibits cross-referenced. Ready the day an exam letter arrives.
• Holding-company / management-company overlay. Where structurally appropriate, management-company carveout memo with economic-substance support, IP holding-company structure, real-estate holding entity — each with 280E and California R&T implications documented. Related-party pricing support drafted.
• Payroll & worker classification review. W-2 vs. 1099 analysis under AB 5 and the ABC test, cannabis-appropriate payroll provider coordination, 280E-aware treatment of direct vs. indirect labor for COGS allocation.
• Banking coordination. Introduction to cannabis-banking-capable institutions (Safe Harbor, FVCbank, and others in the practice’s network), support through account-opening diligence packages, coordination with bank compliance on ongoing MRB reporting expectations. We do not open accounts on your behalf.
• Capital-raise tax positioning. SAFE, convertible note, preferred equity, and common equity treatment modeled for the investor packet. Tax-structure diagram ready for institutional diligence. Related-party and 280E implications of the round documented before counsel drafts.

Format and delivery

Memoranda delivered as editable Word and final PDF. Allocation files delivered as structured Excel workbooks with formulas and citation columns. Reconciliations delivered quarterly. All documents retained seven years.

Defensibility anchor

Every recommendation cites a specific federal or state tax authority. IRC 280E, 471, 263A for federal treatment. Champ, Olive, Patients Mutual, Alternative Healthcare Advocates, Harborside for judicial guidance. R&T Code 34010 et seq. for California cannabis excise. R&T 17209 and 24436.1 for state conformity. CDTFA cannabis tax regulations for collection mechanics. Plus local cannabis business tax ordinances.

What’s not included

Tax return preparation, tax filings, IRS representation, Tax Court advocacy, securities-law compliance, and investment advice are explicitly outside this scope. Where those are needed, we coordinate with your CPA, tax counsel, or securities counsel; we do not perform their work.

Deliverables are what we produce. Outcomes are what those deliverables enable — the specific operational benefits of cannabis tax work done right. 280E remains federal law until rescheduling moves cannabis out of Schedule I; until then, every documented dollar of inventoriable cost is a dollar that stays with the business.

The ten outcomes, in detail

• Optimized 280E exposure. Inventoriable costs allocated under IRC 471 and 263A with supporting documentation; non-inventoriable costs identified without creative interpretation. Typical engagement surfaces meaningful federal tax savings in year one.
• Audit-ready 280E file. Treatment memorandum, COGS allocation worksheets, related-party agreements, entity diagram, tax-position narratives, exhibits cross-referenced. Ready the day an IRS exam letter arrives — not after.
• Cost-seg savings captured. Engineering-based cost segregation separates personal property, land improvements, and building components for MACRS acceleration. Year-one depreciation step-up materially reduces current-year federal tax.
• California excise and CDTFA reconciled. Quarterly cannabis-excise filings reviewed and reconciled against METRC and GAAP revenue. Post-AB 195 retailer-collection compliance verified. Local cannabis-business-tax aligned.
• Entity structure aligned to 280E reality. Licensed entity boundary drawn around the activity 280E governs. Management-company carveout (where structurally appropriate) with economic-substance support documented. IP and real-estate holding entities where warranted.
• Payroll and worker classification compliant. W-2 vs. 1099 analysis under AB 5 and the ABC test. Direct-labor portion of payroll allocated to COGS for 280E-favorable treatment. Cannabis-appropriate payroll provider in place.
• Banking access coordinated. Introduction to cannabis-banking-capable institutions (Safe Harbor, FVCbank, and others in our network). Diligence package for account opening prepared. Ongoing MRB-reporting expectations met. We don’t open accounts on your behalf.
• Diligence-ready tax packet. Institutional investors expect a specific tax-position diagram and narrative. The packet we produce answers diligence questions before they’re asked and shortens raise timelines by weeks.
• Capital-raise tax positioning ready. SAFE, convertible note, preferred equity, and common equity treatment modeled. Related-party and 280E implications of the round documented before counsel drafts term sheet.
• Federal-reform positioning. If and when cannabis moves to Schedule III, 280E effectively sunsets for cannabis. The file we maintain positions the business to pivot immediately — without scrambling to reconstruct the past three years of records that rescheduling will make exam-relevant.

How we measure

Three quantitative measures: (1) documented federal tax savings under 280E COGS allocation vs. baseline — typically 15–35% reduction for well-structured operators; (2) CDTFA reconciliation variance between excise filings and METRC transfers — target under 1%; (3) audit-exposure items identified and remediated in the 280E file — target zero open items. Reported quarterly.

Post-engagement review

At year-end, a structured review: 280E file audited against the year’s filings, cost-seg depreciation verified, CDTFA reconciliation confirmed, structure recommendations measured against actual outcomes. Written year-end memo becomes the baseline for the next year’s engagement and for any IRS exam. Retainer clients roll into ongoing quarterly coordination; standalone clients receive a review memo at year-end.

When IRS asks why a cost is allocated to COGS, we cite IRC 471. When CDTFA asks about an excise adjustment, we cite Regulation 3700. When Tax Court case law supports a position, we cite the case by name. Financial and tax advisory for cannabis sits on a stack of federal statute, case law, and California-specific tax authority.

The citations, in detail

• IRC 280E — Trafficking in controlled substances. Federal statute disallowing deductions and credits for any trade or business trafficking in Schedule I or II controlled substances. Cannabis remains Schedule I. In practice, 280E is the foundational constraint on every federal tax position — and the case law interpreting it defines what the statute actually means for cannabis operators.
• IRC 471 — Inventory methods. Sets the general rule for inventory accounting and, critically, establishes the boundary between inventoriable (COGS) and non-inventoriable costs. In practice, 471 is the statute that permits COGS deduction despite 280E — IRS and Tax Court have repeatedly held that COGS is not a “deduction” within 280E’s meaning, so properly allocated inventoriable costs remain recoverable.
• IRC 263A — Uniform capitalization. Extends 471 inventoriable treatment to additional indirect costs for producers. Interacts with 280E: post-Patients Mutual, IRS has taken increasingly narrow positions on 263A for cannabis producers, and case law is still evolving. In practice, producer-side 263A positions require careful documentation and well-supported absorption methods.
• Champ, Olive, Patients Mutual, Alternative Healthcare Advocates, Harborside. The governing Tax Court and appellate case law on 280E for cannabis. Champ (2007) first addressed the separate-trade-or-business framework; Olive (2015) affirmed 280E applies to medical dispensaries; Patients Mutual (2018) sharply limited 263A for producers; Alternative Healthcare Advocates further clarified the scope. In practice, every 280E memo cites the governing case by holding, not just by name.
• R&T Code 34010 et seq. — California cannabis tax. State excise and cultivation-tax regime. AB 195 (effective 2023) restructured the excise collection point from distributor to retailer. In practice, this is the statutory basis for CDTFA cannabis-tax filings and for the distributor-to-retailer invoice flow.
• R&T Code 17209 and 24436.1 — California 280E conformity. California’s conformity (or non-conformity) with federal 280E treatment. California partially decouples for personal-use cultivation and some medicinal activity; commercial California cannabis follows federal 280E treatment for state income-tax purposes. In practice, state conformity is the trickiest layer of the analysis — CPAs who miss it either over- or underpay California tax.
• CDTFA Regulation 3700–3712 — Cannabis tax collection. The administrative framework for excise-tax collection, distributor obligations (pre-AB 195) and retailer obligations (post-AB 195), return requirements, and audit authority. In practice, these regulations plus ongoing CDTFA Special Notices are the operational rules for tax compliance.
• Rev Rul 67-246 and related guidance. Revenue rulings and related IRS guidance on inventory costing, absorption methods, and indirect cost allocation. In practice, these rulings provide the framework within which cannabis-specific 280E positions are built.
• Local cannabis business-tax ordinances. LA Measure M, SF cannabis tax, Oakland cannabis tax, Sacramento cannabis tax, and every other local cannabis-specific business tax. In practice, local tax reconciliation sits alongside CDTFA reconciliation; local rates vary widely and rules change on council calendars.
• AB 5 and the ABC test — Worker classification. California’s worker-classification framework determining W-2 vs. 1099 status. In practice, proper classification affects both compliance (Labor Code) and 280E COGS allocation (only W-2 direct labor flows cleanly into cannabis COGS).

Interaction between authorities

Cannabis tax sits in a three-layer stack: federal income tax (IRC 280E, 471, 263A plus case law), California income tax (R&T conformity, 17209, 24436.1), and California excise/local tax (R&T 34010 series, CDTFA Regulation 3700 series, local ordinances). Each layer has its own rule set; a position that’s right federally can be wrong for California, and vice versa. Worker-classification under AB 5 and the case law on 280E indirect-cost absorption interact at the COGS-allocation boundary. The engagement works all three layers simultaneously because ignoring any one creates exposure in another.

Scope, pricing, timelines, edge cases — the questions operators and CFOs actually ask about cannabis tax work in the federal-Schedule-I era.

• Are you CPAs? No. GreenState Group is a regulatory consulting firm, not a CPA firm. We don’t prepare returns, file tax filings, or represent clients before IRS or CDTFA in audit or appeal. Our work is structural and strategic: 280E treatment analysis, COGS allocation documentation, entity structure, cost segregation, and IRS-exam file maintenance. We coordinate with your CPA of record on every engagement and, if you don’t have a cannabis-specialized CPA, we introduce one from our network.
• What’s the biggest 280E mistake? Not separating inventoriable from non-inventoriable costs clearly under IRC 471 and 263A. Operators either over-allocate to COGS (exposure on exam) or under-allocate (overpays tax). A systematic, documented allocation can preserve substantial COGS deduction while staying defensible. The second-biggest mistake is treating all labor as inventoriable; only direct production labor flows cleanly — indirect labor (admin, sales) does not.
• Does federal reform change this? If and when cannabis moves from Schedule I to Schedule III, 280E no longer applies to cannabis by its terms — 280E disallows deductions only for Schedule I and II substances. We track rescheduling proceedings and help operators position for the pivot: records structured so that a mid-year rescheduling can be operationally absorbed rather than remediated. Timing is unknown; the structure is worth having regardless.
• Cost-segregation ROI? Typical engineering-based cost-segregation study pays for itself in year-one accelerated depreciation for manufacturers with extraction capex, indoor cultivators with lighting and HVAC capex, and facility operators with significant tenant-improvement investment. We model the before-and-after at Week 1 so the decision is data-supported rather than promissory. Retail operators typically see less benefit than cultivators or manufacturers.
• How does this work with our CPA? We coordinate with your existing CPA on every deliverable. The 280E memo goes to your CPA with the COGS allocation workbook; your CPA uses both to prepare the return. Quarterly CDTFA reconciliations go to your CPA for tax-filing support. If you don’t have a cannabis-specialized CPA, we introduce one from our network — we don’t replace your CPA; we support them.
• What about CDTFA excise specifically? Post-AB 195 (effective 2023), excise-tax collection shifted from distributor to retailer. Distributor remittance is based on invoiced amounts rather than fair-market value estimates. We reconcile the quarterly filing against METRC transfers and GAAP revenue; mismatches between track-and-trace data and tax filings are the fastest way to draw a CDTFA audit. Most operators we engage have reconciliation variance that reduces on ongoing coordination.
• What about management-company structures? Where structurally appropriate, a separate management company that provides non-cannabis services (HR, accounting, marketing, IT, facilities) can operate outside 280E if structured with economic substance and arm’s-length pricing. The Patients Mutual line of cases sets meaningful limits; not every operator can use this structure. We model it and scope coordination with counsel before any restructure.
• How do you handle an IRS audit? We maintain the 280E file throughout the year so that when an exam letter arrives, the record is ready. We don’t represent you before IRS — that’s your tax counsel’s scope — but we provide the underlying tax-position memo, the COGS workbook, the related-party agreements, and the exhibits. Counsel takes it from there. Our work is the record; counsel’s work is the advocacy.
• How do you price engagements? Initial four-week engagement runs $12,000–$35,000 depending on entity complexity and license count. Ongoing quarterly coordination runs $1,500–$3,500 per quarter. Cost-segregation studies run $8,000–$25,000 depending on facility complexity. Ongoing compliance retainer clients get financial and tax advisory at a reduced rate.
• Can you help with banking access? We introduce you to cannabis-banking-capable institutions in our network (Safe Harbor, FVCbank, North Bay Credit Union, and others). We prepare the diligence package needed for account opening and support ongoing marijuana-related-business (MRB) reporting expectations. We don’t open accounts on your behalf — that requires your direct involvement under KYC requirements — but we shorten the onboarding timeline materially.